Shots:

• The P-III SUNRISE 2 study involves assessing of Lemborexant (5mg-10mg) vs PBO in 949 patients with insomnia disorder- characterized by difficulty in falling asleep/staying asleep aged 18 to 88yrs.
• P-III SUNRISE 2 study results: reductions in sleep onset latency (sSOL) (-21.81- -28.21 vs -11.43 min); improvement in sSE (14.19%- 14.31% vs 9.64%); reduction in subjective wake after sleep onset (sWASO) (-46.75- -41.95 vs -29.28 min); presented at Sleep Research Society’s on 14 Feb- 2019
• Lemborexant is an orexin neurotransmitter targeted for faster falling asleep with longer period of time with its NDA filled with the US FDA for insomnia on 27 Dec-2018 and is evaluated in P-II for sleep-wake rhythm disorder and mild to moderate Alzheimer's dementia

Click here    Ref: PRNewswire | Image: Bizjournals